Melanotan II vs Afamelanotide
Both Melanotan II and Afamelanotide are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.
Melanotan II
Evidence C+Melanotan II (MT-II)
A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.
View full Melanotan II profile →Afamelanotide
Evidence AAfamelanotide (Scenesse)
An FDA-approved selective MC1R agonist used to increase eumelanin density in erythropoietic protoporphyria patients. Off-label cosmetic tanning use is widespread internationally.
View full Afamelanotide profile →Side-by-Side
| Attribute | Melanotan II | Afamelanotide |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued | FDA-approved (2019) for erythropoietic protoporphyria (EPP) |
| Typical Dose | 0.25–1 mg daily during loading, then maintenance (subcutaneous) | 16 mg subcutaneous implant every 2 months (clinical use) |
| Clinics Indexed | 18 | 14 |
| Categories | skin, sexual-health | skin |
Key reported benefits — Melanotan II
- ✓UV-independent tanning
- ✓Erectile effect (off-label)
Key reported benefits — Afamelanotide
- ✓MC1R-selective tanning
- ✓FDA-approved for EPP
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.